

PATENT CLAIMS

- 5 1. Use of an α v- integrin antagonist for the manufacture of a medicament for the treatment of pathological conditions in a mammal in which activated fibroblast or myofibroblasts are involved.
- 10 2. Use according to claim 1, wherein the α v-integrin antagonist is an α v β 3 antagonist.
3. Use according to claim 1, wherein the α v-integrin antagonist is an α v β 6 antagonist.
- 15 4. Use of claim 2 or 3, wherein the the α v-integrin antagonist is selected from the group consisting of
- (i) 3-Benzo [1, 2, 5] thiadiazol-5-yl-3-{6-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-1H-indol-3-yl}-propionic acid, and
- (ii) 3-{3-Benzylloxy-2-[5-(pyridin-2-ylamino)-pentanoylamino]-propanoylamino}-3-(3,5-dichloro-phenyl)-propionic acid.
- 20 5. Use according to any of the claims 1 – 4, wherein the pathological condition is fibrosis or a fibrotic disease.
- 25 6. Use according to claim 5, wherein the fibrosis is a fibrotic liver disease.
7. Use according to claim 6, wherein said fibrotic liver disease is liver cirrhosis.
- 30 8. Use according to claim 5, wherein said antagonist inhibits PDGF-induced HSC/MF migration and / or activation.
9. Use according to claim 5, wherein said antagonist inhibits scarring.